AACR: Urine Test May Predict Lung Cancer Risk
High levels of tobacco-specific nitrosamine metabolites linked to nearly nine-fold higher risk
MONDAY, April 20 (HealthDay News) -- In smokers, urinary levels of tobacco-specific nitrosamine metabolites are associated with an increased risk of lung cancer, according to research presented at the 100th Annual Meeting of the American Association for Cancer Research held from April 18 to 22 in Denver.
Jian-Min Yuan, M.D., of the University of Minnesota in Minneapolis, and colleagues analyzed data from the Shanghai Cohort Study and the Singapore Chinese Health Study which respectively included 18,244 men ages 45 to 64 years and 63,257 men and women ages 45 to 74 years.
After adjusting for self-reported smoking history and urinary total cotinine, the researchers found that subjects in the second and third tertiles of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) had increased risk compared to those in the lowest tertile (odds ratios, 1.43 and 2.11, respectively). They also found that subjects in the highest tertiles of NNAL and total cotinine had an 8.5 times higher risk compared to those in the lowest tertiles.
"Total NNAL and total cotinine in urine are important predictors of lung cancer in smokers beyond the predictive indices of smoking intensity and duration," the authors conclude. "These two non-invasive biomarkers can serve as the starting point of an individual-based, predictive model for lung cancer risk in a smoker."